Key Takeaways
- Base business steady, battery delayed: Consolidated revenue grew 20% YoY driven by organic chemicals, but battery chemicals guidance was cut to ₹50-₹75 crore from ₹75-₹100 crore as site approvals took longer than expected.
- Margins improved on lithium price normalization: EBITDA margin expanded 180 bps to 17.9%, helped by lower lithium prices (denominator effect) and BuLi Chemicals turning profitable; the battery segment remains a drag, still below break-even.
- Battery ramp-up is now a Q3/Q4 story: First 200 MTPA of electrolyte salts capacity is commissioned with initial customer approvals in hand, but volumes depend on customers clearing parallel audits and scaling their own trial production to regular output.
- FY26 battery ambition is large but unguided: Management sees a "very strong possibility" of ₹400-₹500 crore in battery chemicals next year, yet explicitly declined to call it guidance, asking for more time.
- What to watch next quarter: Whether electrolyte customer audits convert to purchase orders, the pace of BuLi Chem capacity expansion once state environmental clearance arrives, and any recovery signal in agro CSM from Japanese customers by January.
Battery Chemicals: The Approval Bottleneck
- Guidance cut, not demand destruction: The FY25 battery revenue revision from ₹75-₹100 crore to ₹50-₹75 crore reflects longer site-approval timelines for some salts, not weaker customer interest. Management was explicit that next year and the year after are unchanged.
- Electrolyte salts: contracts exist, audits remain the gate: Pricing, volume, and terms are already agreed with some customers. What remains is a rigorous parallel audit where production is done in front of the customer. Once audits clear, purchase orders start flowing and shipping time is short.
- Electrolyte trials progressing, but customers are still in trial production: Some domestic customers have taken trials, seen satisfactory performance, and are ready to place bigger volume orders. The bottleneck is that customers themselves are still in trial production phase; as their trial production becomes regular, Neogen's electrolyte volumes rise.
- Customer learning deepens Neogen's moat: Through trials, Neogen is gaining understanding of which electrolyte works better for different cell designs. They collaborate with Mitsubishi to help design electrolytes for customers, and are now part of the design process from the beginning, especially optimizing for India's high-temperature conditions.
- Greenfield MUIS facility on track for FY26: Financial closure is secured, civil construction has started, and Mitsubishi has begun plant construction at their end. Commissioning remains phased in FY26 as originally planned.
- International salt demand provides a second engine: Strong demand for non-Chinese products is visible; ongoing discussions and MOUs are expected to secure business from the MUIS site.
Dr. Harin Kanani: "The first six months, the approvals have taken longer time for the new site, especially for some of the salts. So, based on that today what I am looking at is the best for this particular year for battery would be somewhere around Rs. 50 crore to Rs. 75 crore. But next year or the year after, I don't see any change."
Base Business: Organic Strength, Inorganic Drag
- Organic chemicals grew 34% YoY, driven by BuLi Chemicals, non-agro CSM, bromine derivatives, and lithium derivatives volume. Inorganic chemicals declined 24%, mainly on lower lithium prices.
- BuLi Chemicals turned profitable over the last two quarters and is now contributing to margins after being a drag earlier. A five-year pharma contract for bromine derivatives continues to scale as the molecule gains approvals.
- Non-agro CSM reached 15-18% of revenue despite lower agro demand, driven by semiconductor, flavors and fragrance, and specialty polymer applications. Agro CSM has not picked up this year; Japanese customers start planning from October, with clarity expected by January.
- Advanced intermediates remain weak, still impacted by Chinese competition and lower demand in bulk APIs.
- Lithium recycling is a quiet volume lever: Neogen started recycling lithium that was previously given out externally, helping increase lithium volumes despite depressed prices.
- Lithium and bromine pricing: absolute EBITDA protected: Historically, when lithium prices swung, absolute EBITDA was largely protected except for one or two quarters. The percentage looked lower when prices were high, but absolute EBITDA was not an issue. The exception was an inventory hit when BuLi Chemicals was taken over and imported expecting high demand just before a sharp price correction. Otherwise, back-to-back POs maintain absolute margins. Pressure on absolute EBITDA comes from advanced intermediates and bromine derivatives where Chinese competition forces price corrections.
Dr. Harin Kanani: "That 1,000 at the max would change to 1,050, but with all the other things happening in the agro world, etc., I would like to keep that Rs. 50 crore as my buffer and I would like to still maintain Rs. 1,000 crore."
Margin Walk: Lithium Help, Battery Drag
- EBITDA margin expanded 180 bps YoY to 17.9%. The improvement was largely driven by lithium price corrections (a lower denominator effect on the inorganic segment) and BuLi Chemicals turning profitable.
- Battery segment still a drag: The battery chemicals business generated only single-digit crore revenue while carrying ongoing expenses, keeping it below break-even.
- Other overheads dipped ~10% QoQ, but management had not examined the move closely. Possible explanations include provisions that were kept on the higher side and later corrected, or more accurate expense bifurcation across Neogen Chemicals, Neogen Ionics, and BuLi Chemicals as they share common facilities.
- ROCE protection is the pricing anchor: On battery chemicals, management is targeting to protect a 20% ROCE, framing it as the return the risk they are taking deserves.
Dr. Harin Kanani: "we are basically targeting to protect our 20% ROCE, which we feel something like the risk that we are taking is what we deserve."
Capacity Expansion & Corporate Structure
- BuLi Chemicals merger applied for: Applications are going online, and the merger is expected to complete by the end of the current financial year, with BuLi Chem likely appearing in standalone results next financial year.
- BuLi Chem capacity: 2x expansion ready to go: Centre's environmental clearance is received; state-level approval is awaited. Management noted that with very small capex, a 2x capacity increase can be executed, and total capacity can grow up to five times. State approval is expected in the next three months or so.
- Dahej electrolyte plant: first phase operational: The initial 200 MTPA is commissioned with more than four customers approved at a commercial level. The remaining 200 MTPA is in trial production and optimization; both facilities are expected to be fully online and approved before the end of the current financial year.
- Debt tie-up nearly complete: What is needed for the Pakhajan greenfield site is fully tied up. For the Dahej capacity increase, it is partially tied up with the remainder in final stages. Another close to ₹100 crore is almost tied up. Management is putting in their own money to ensure no delay.
- Neogen Ionics rating process is completing independently; post that, the remaining debt is expected to close this quarter.
Dr. Harin Kanani: "We have a capacity to grow up to five times. We have already applied for environment clearance and have already received Centre's approval on that. Now, we are working at the state level approval and fortunately, with a very small CAPEX, 2x capacity increase, we can do..."
Medium-Term Roadmap: Three Horizons
- FY25-FY27: stabilize the base business. Management wants to make the base business more efficient on margins, working capital, and product mix. Battery stabilizes through FY25-26-27. BuLi Chemicals gets completely utilized, hopefully at 2x capacity, and synergies start playing out.
- FY28-FY29: CSM becomes the growth engine. The work done on CSM in the interim will allow rapid growth. A single customer who can give significant hundreds of crores of revenue is expected to ramp up from FY28 onwards. The main CSM push happens when Neogen sets up a specific plant for a specific molecule (₹150-₹200 crore single molecule) beyond FY27.
- Battery chemicals: ₹1,000 crore-plus ambition for FY27. Management said it should be above ₹1,000 crore, though how much above depends on how the electrolyte business develops and how the salt market plays out. They declined to give a firmer number, calling it "just a view" and promising clearer guidance only next financial year.
- 30 GWh is the electrolyte target over a 3-5 year horizon, which management described as "peanuts" relative to the 3,000 GWh global opportunity.
- India's competitiveness thesis: Management believes that outside China, India is the best potential place to make cells globally on a long-term basis because of local demand, skill set, manpower, expertise, and land. As scale grows to tens and hundreds of gigawatt-hours, the gap with China will narrow.
Dr. Harin Kanani: "outside China, the best potential place to make cells globally on a long-term basis is India because like China, we have the local demand also, which can be significantly high."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Battery chemicals FY25 revenue | ₹50-₹75 crore (revised from ₹75-₹100 crore) | FY25 |
| Remaining 200 MTPA electrolyte capacity | Fully online and approved | Before end of current financial year |
| Greenfield MUIS facility commissioning | Phased commissioning | FY26 |
| BuLi Chemicals merger with Neogen | Completed, BuLi Chem in standalone results | End of current financial year |
| BuLi Chem 2x capacity expansion | Execution begins | As soon as state environmental clearance received (next ~3 months) |
| Base business revenue FY26 | ₹950-₹1,000 crore (includes BuLi Chem) | FY26 |
| Base business revenue FY27 | ₹1,150-₹1,200 crore | FY27 |
| CSM share of revenue | 20% | FY26 |
| Net working capital days | 130-140 days | Next financial year |
| Battery chemicals FY26 revenue | ₹250 crore base; ₹400-₹500 crore "very strong possibility" (not formal guidance) | FY26 |
| Battery chemicals FY27 revenue | Above ₹1,000 crore (not formal guidance; clearer guidance promised next financial year) | FY27 |
| ROCE on battery chemicals | Protect 20% | Ongoing |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹193 cr, +20% YoY |
| EBITDA | ₹35 cr, +33% YoY |
| EBITDA margin | 17.9%, +180 bps YoY |
| Profit after tax | ₹11 cr, +30% YoY (management stated); +38% YoY (CFO stated) |
| Organic chemicals revenue | ₹164 cr, +34% YoY |
| Inorganic chemicals revenue | ₹29 cr, -24% YoY |
| Organic revenue adjusted for raw material price fall | ~₹186 cr (Q2 FY25) |
| Inorganic revenue adjusted for raw material price fall | ~₹55 cr (Q2 FY25) |
| Domestic and export mix | 74% domestic, 26% export |
| Battery chemicals revenue guidance FY25 | ₹50 cr to ₹75 cr, revised from ₹75 cr to ₹100 cr |
| Base business revenue guidance FY26 | ₹950 cr to ₹1,000 cr (includes BuLi Chem) |
| Battery chemicals revenue possibility FY26 | ₹400 cr to ₹500 cr |
| Base business revenue target FY27 | ₹1,150 cr to ₹1,200 cr |
| Battery chemicals revenue view FY27 | Above ₹1,000 cr |
| CSM share of revenue | 15-18% in recent quarters, target 20% by next year |
| BuLi Chemicals utilization | Near full capacity |
| Lithium derivatives volume growth | ~30-40% YoY |
| Core business volume growth | ~50% YoY (per an analyst's math) |
| Battery materials CAPEX spent to date | ₹350 cr to ₹400 cr out of ₹1,500 cr plan |
| Full-year CAPEX target FY25 | ₹700 cr to ₹750 cr |
| Working capital target by next FY | 130-140 days net working capital on net sales days basis |
| Battery business working capital target | ~90 days cycle |
| Lithium electrolyte salt capacity expansion | 400 MT to 2,500 MT underway |
| Electrolyte plant Dahej phase 1 commissioned | 200 MT, more than four customers approved at commercial level |
| Lithium electrolyte salts and additives capacity commissioned | First 200 MTPA of 400 MTPA total |
| Debt tied up for battery CAPEX | ~₹900 cr with SBI; additional ~₹100 cr almost tied up |
| ROCE target for battery chemicals | 20% |
| Lithium price expectation stable scenario | $20 to $25 per kg |
| Salt realization range | $28 to $35 per kg |
| Electrolyte realization range | $8 to $9 per kg |
| Companies engaged in India for battery materials | 30-35 companies in India, 40-45 internationally |
| Electrolyte capacity target | 30 GW hour |